See the DrugPatentWatch profile for Alemtuzumab
What class is alemtuzumab in?
Alemtuzumab is a monoclonal antibody (mAb) medicine. It belongs to the immunotherapy category used in certain autoimmune diseases and some blood cancers. [1]
What does it target (its mechanism)?
Alemtuzumab targets CD52, a surface antigen found on many immune cells. By binding CD52, it depletes specific immune cell populations. [1]
How is it commonly used clinically?
Alemtuzumab is used as an immunosuppressive/immune-depleting therapy in conditions where reducing harmful immune activity is beneficial, including:
- Multiple sclerosis (in selected patients, under specific protocols) [1]
- Certain hematologic malignancies (blood cancers) [1]
Is it an antibody for cancer or autoimmune disease?
It is used for both, depending on the indication and dosing regimen. In cancer settings it acts through immune modulation/target binding, while in autoimmune settings it reduces disease-causing immune activity via targeted immune cell depletion. [1]
Are there related drug classes to compare with?
Alemtuzumab is part of the broader monoclonal antibody drug class, alongside other mAbs used in autoimmune disease and hematologic cancers. What differentiates it is the specific target (CD52) and its immune-depleting effect. [1]
Sources:
[1] https://en.wikipedia.org/wiki/Alemtuzumab